Clinical Trials Browser

NIH × Prednisone × Genitourinary × Clear all

NCT04633252 2026-04-08

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT03860987 2025-09-08

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

Phase 2 Active not recruiting

Castrate Sensitive Prostate Cancer

NCT01576172 2020-11-12

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

159 enrolled 12 charts

Prostatic Neoplasms

NCT01683994 2019-11-08

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

Phase 1/2 Completed

49 enrolled 18 charts

Prostatic Neoplasms

NCT01553188 2019-03-05

AMG 386 and Abiraterone for Advanced Prostate Cancer

Phase 2 Completed

36 enrolled 18 charts

Prostatic Neoplasms

NCT00942578 2018-10-11

A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

Phase 2 Completed

63 enrolled 23 charts

Prostatic Neoplasms

NCT00436956 2018-10-09

AZD2171 to Treat Prostate Cancer

Phase 2 Completed

59 enrolled 12 charts

Prostatic Neoplasms

NCT00634647 2018-10-02

Satraplatin and Prednisone to Treat Prostate Cancer

Phase 2 Completed

24 enrolled 12 charts

Prostatic Neoplasms

NCT00527124 2018-08-09

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Terminated

57 enrolled 12 charts

Prostatic Neoplasms

NCT00089609 2018-04-20

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

Phase 2 Completed

73 enrolled 16 charts

Neoplasms, Prostatic Neoplasms

NCT00331344 2017-10-31

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

Phase 1/2 Completed

100 enrolled 10 charts

Prostatic Neoplasms

NCT01145508 2017-09-19

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 2 Terminated

10 enrolled 6 charts

Prostatic Neoplasms

NCT00058084 2017-02-23

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00110214 2014-05-09

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 3 Completed

1,050 enrolled 13 charts

Prostatic Neoplasms

NCT00003633 2013-12-19

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

Phase 1 Unknown

Prostatic Neoplasms

NCT00255606 2013-06-26

Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT00627354 2011-05-16

Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2 Completed

Prostatic Neoplasms